This is a small molecule inhibitor of the KRAS G12C mutated protein. Used for some people that have this particular mutation in Small Cell Lung Cancer. 30 to 50% of Colon cancers have KRAS Mutations and only a small percentage of those (3 to 4%) are of the G12C variety. In Small Cell Lung Cancer up to 40% of the people with KRAS mutations are of the G12C variety, but only about 30% of people with Lung Cancer have KRAS Mutants. It's not likely that LUMAKRAS will have a big impact on Colon Cancer treatment. Most likely only for a very few people that have been tested and been found to harbor that particular mutation. But the market is much better for those with Lung Cancer.
GrouseMan